Recipharm Extends Partnership with Sato Pharmaceutical

Recipharm has entered into a long-term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of the Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato.

Recipharm’s facility in Karlskoga, Sweden will produce and deliver the product to Sato, which has headquarters in Tokyo. Recipharm says after a successful launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.

"We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further," said Ingela Palmkvist, general manager at Recipharm in Karlskoga. "We are looking forward to the launch in Japan and cooperating with Sato in developing the business to the benefit of both companies."